Abstract: Embodiments of the present disclosure provide a precoding matrix indication method, user equipment, and an access device. The precoding matrix indication method includes: generating indication information, where the indication information indicates KNZ - v non-zero weighting coefficients, the KNZ - v non-zero weighting coefficients belong to KNZ non-zero weighting coefficients, v is a quantity of transport layers, the KNZ non-zero weighting coefficients are for constructing a precoding matrix, and the precoding matrix is constructed based on at least the KNZ non-zero weighting coefficients, m spatial domain vectors, and n frequency domain vectors, where the indication information is generated in a first manner when a first preset condition is met, or the indication information is generated in a second manner when a second preset condition is met; and sending the indication information.

Abstract: The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.

Abstract: The present disclosure relates to a drug combination for treating non-small cell lung cancer, in particular to uses of ergosterol combined with gefitinib, and belongs to the technical field of biomedicine. In the present disclosure, the mechanism of action that ergosterol (ERG) combined with gefitinib (GEF) induces apoptosis of non-small cell lung cancer (NSCLC) cells is firstly studied; then an RGG cyclic peptide/R8 peptide modified ERG combined with GEF active drug-loaded targeted liposome delivery system (RGD/R8-ERG/GEF-LIP) is constructed; and the RGD/R8-ERG/GEF-LIP is prepared into a freeze-dried powder to improve stability, quality evaluation and preliminary evaluation of in vitro anti-lung cancer effects are conducted, and a nude mouse lung cancer xenograft model is established for conducting preliminary pharmacodynamic research and in vivo targeting research.

Abstract: The presently disclosed subject matter is directed to an RGD peptide and penetrating peptide R8 co-modified ergosterol and cisplatin active drug-loading liposome that is prepared by means of the incubation of an ergosterol and cisplatin active drug-loading liposome, RGD cyclic peptide, and penetrating peptide R8 in a water bath. The ergosterol and cisplatin active drug-loading liposome is prepared from an ergosterol liposome and a cisplatin solution serving as the raw materials. The ergosterol liposome is prepared from 8 wt % to 15 wt % ergosterol and 85 wt % to 92 wt % liposomes, and the liposomes consist of lecithin and cholesterol.